What INEXION does

INEXION operates a two-product platform built around a multi-source longitudinal health registry of de-identified longevity-medicine outcomes. The core registry combines three layers — an 8-dataset public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare; first three deployed in production, fourth arriving), de-identified contributions from cash-pay longevity clinics, telehealth platforms, and EHR partners under standard Data Use Agreements, and medical-society data flows via A4M and Longevity Docs — all unified under a single schema enforced at the integration layer. The schema-aligned architecture is the central technical decision: it lets INEXION add partners without acquisition CapEx, applies HIPAA Safe Harbor de-identification at source (18 specified identifiers), and makes data quality compound with each new contributor. The second product, INEXION Clocks, is practice-management software for longevity clinics that surfaces biological-age clock analytics, protocol-level outcome tracking, longitudinal patient timelines, and network benchmarking against the registry; demo complete with first deployments targeted for summer 2026.

The registry is the primary revenue engine. INEXION licenses data across four transaction-based streams: pharma HEOR studies ($150K-$400K each, 80%+ gross margin), sponsor-funded real-world evidence studies ($75K-$500K each, 75-85% margin), distributed trial-site identification and network access ($50K-$500K per engagement, 60-70% margin), and AI/ML training dataset subscriptions ($200K-$500K/year, 90%+ margin — highest-margin line). Customer segments are four named verticals: pharma HEOR and clinical operations at Lilly, Novo Nordisk, Pfizer, Amgen; longevity biotech R&D at Insilico, Life Biosciences, Rubedo (145+ active anti-aging trials worldwide); CROs and pharma sponsors for distributed trial-site networks; and AI/ML data science teams at Tempus, Saama, and similar firms. Go-to-market pairs an enterprise field-sales motion (direct outreach, discovery conversations under NDA, early-access partner program, joint study design) with a partner-led contributor enrollment model for clinics, telehealth platforms, EHR vendors, and medical societies. Ownership is founder-led, family-office-backed at seed (FO-led round targeting Q3 2026 close, extendable SAFE), with the company explicitly avoiding traditional VCs at seed to avoid exit pressure; Series A of $10-15M is structured FO-led with 1-2 strategic healthcare VCs co-investing, triggered on a Gate 2 composite of $500K ARR + 2+ active LOIs + 25K patient records + 3+ Type-1 partners by May 2027. Long-term pre-money targets are $40-53M at Series A, $150-180M+ at 2028 scale, and $500M-$1B at platform maturity, framed against comps Flatiron ($1.9B to Roche), Komodo ($3.3B), and IQVIA ($3.5B+ analytics revenue).

Name

INEXION

Legal name

INEXION Holdings, LLC

Website

https://inexion.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

INEXION operates a multi-source longitudinal registry of de-identified cash-pay longevity medicine outcomes, integrating a public-dataset spine with clinic, telehealth, EHR, and medical society data contributions for licensing to pharma HEOR, biotech R&D, CRO, and AI/ML buyers, alongside INEXION Clocks practice-management software for longevity clinics.

Ownership category

akta.pro rank

Product category

Real-World Evidence Data Platform

SIC

Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Programming Services (7371), Services-Prepackaged Software (7372)

akta.pro primary industry

Patient Registries & Chronic Disease Registry Analytics (HLACAHAH)

akta.pro secondary industries

Clinical & Claims Data Integration for Population Health (payer-provider data fusion) (HLACAHAI), Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM)

Keywords

• Real-world evidence data
• Longevity medicine registry
• De-identified health data
• Practice management software
• HEOR data licensing

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Pharma HEOR Data Licensing: De-identified longitudinal registry licensed to pharma HEOR teams (Eli Lilly, Novo Nordisk, Pfizer, Amgen) running longevity-adjacent programs (GLP-1s, senolytics, NAD+ pathway modulators). $150K–$400K per study. Primary value-creation engine expected to re-rate business to platform multiples (15–20×+) at scale. 80%+ gross margin.
2. Real World Evidence (RWE) Studies: Sponsor-funded RWE through the partner network — registry data fees plus protocol-based study fees for comparator data, biomarker validation, and label expansion support. Buyers: Insilico Medicine, Life Biosciences, Rubedo Life Sciences. $75K–$500K per study. 75–85% gross margin. Network-effect compounding as partner base grows.
3. Distributed Trial Site Network Identification: Site identification, qualification, and contracting fees from sponsors and CROs (Parexel, Syneos, ICON) — without operating the sites. $50K–$250K per matched site, plus $100K–$500K trial-network access fees. Uncontested category; no legacy network operates in longevity. 60–70% gross margin.
4. AI/ML Training Datasets: Multimodal longitudinal longevity data (EHR, wearable, PRO, imaging, genomic) licensed as training corpus to AI/ML programs across pharma and biotech, plus data science teams at Tempus, Saama, and similar firms. $200K–$500K per year. 90%+ gross margin — highest-margin revenue line. Data currently unbuyable in any form.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

INEXION builds and licenses a multi-source longitudinal health registry of cash-pay longevity patients — the cohort invisible to every claims-based data platform — by integrating a public-data spine (NHANES, BRFSS, HRS, etc.) with de-identified contributions from partner clinics, telehealth platforms, EHRs, and medical societies under a unified schema enforced at the integration layer. INEXION also sells INEXION Clocks, practice management software for longevity clinics featuring biological-age analytics, protocol tracking, and network benchmarking powered by the registry.

Product overview

INEXION operates a two-product platform serving the longevity medicine market: (1) the INEXION Registry — a multi-source longitudinal health registry combining a public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare), private partner contributions from longevity clinics and telehealth platforms, and medical society partnerships (A4M, Longevity Docs), structured under a unified schema enforced at the integration layer; and (2) INEXION Clocks — practice software for longevity clinics providing biological-age analytics, protocol tracking, longitudinal patient timelines, and network benchmarking built in. The two products form a flywheel: INEXION Clocks generates the de-identified patient data that feeds the registry, while the registry provides the benchmarking intelligence surfaced within Clocks. The registry is the primary revenue engine, licensed to pharma HEOR teams, biotech R&D, trial site networks, and AI/ML teams across four buyer segments.

Differentiator

Problem solved

Functional benefit

Products and services

• INEXION Registry A multi-source longitudinal health registry aggregating de-identified longevity medicine outcomes across three data layers: a public-data spine (NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare), private partner contributions from longevity clinics and telehealth platforms, and medical society partnerships. Schema-enforced at the integration layer. Licensed to pharma HEOR teams, biotech R&D, clinical trial site networks, and AI/ML data science teams for HEOR studies, RWE, trial site identification, and AI/ML training datasets.
• INEXION Clocks Practice management software built for longevity clinics, featuring biological-age analytics, protocol tracking, longitudinal patient timelines, and network benchmarking against de-identified peers powered by the INEXION registry. Operates as a thin overlay on existing systems without EHR migration, with HIPAA-grade privacy and standard Data Use Agreement onboarding. Early-access clinics receive founding pricing and direct line into product roadmap.

Quantifiable outcome

• $2.7B reference market (RWD licensing) growing to $7.1B by 2033 with zero longevity coverage in incumbent platforms
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and major.

• HealthspancoreStrategic or Co-development Partner · 1 February 2026Los Angeles-based longevity clinic. Data exchange agreement structured for data contribution and licensing revenue share. Activates Q3 2026. One of the first anchor partners for the INEXION registry, establishing the partnership model for future clinic integrations.
• AgelessRxcoreStrategic or Co-development PartnerIn late-stage negotiation for data contribution to the INEXION registry. Partnership would add a high-volume telehealth platform to the partner network, expanding the cash-pay longevity cohort captured in the registry.
• Reya.aicoreTechnology or IntegrationNamed as Track 2 EHR partnership lead with term sheet target October 2026. Reya.ai would serve as an EHR integration partner enabling structured data flow from longevity practices into the INEXION registry schema.
• A4M (American Academy of Anti-Aging Medicine)majorStrategic or Co-development PartnerIn active partnership discussions. Society partnership brings physician network breadth — practitioners contribute to the registry under a unified schema. A4M is the largest professional organization in anti-aging and longevity medicine.
• Longevity DocsmajorStrategic or Co-development PartnerIn active partnership discussions. Medical society partnership to drive physician network breadth and registry contributor recruitment. Jointly advances the longevity medicine evidence base.
• NHANES, BRFSS, HRS, MIDAS, All of Us, UK Biobank, MIDUS, CMS Medicare (Public-Data Spine)coreOthersEight public datasets form the population baseline spine of the INEXION registry. NHANES, BRFSS, and HRS deployed today. MIDAS arriving within weeks. All of Us, UK Biobank, MIDUS, and CMS Medicare in pipeline. Provides population-level baseline for cohort comparisons against private partner cohorts.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Truveta: Truveta aggregates de-identified EHR data from a health-system consortium under a unified schema for life sciences licensing, structurally similar to INEXION's partnership-led schema-enforced registry model.
• Panalgo (Norstella): Panalgo provides real-world evidence analytics software that lets life sciences teams run analyses against large healthcare datasets, overlapping with INEXION's pharma RWE use cases.
• Atropos Health: Atropos Health delivers on-demand real-world evidence from de-identified clinical data to clinicians and life sciences teams, competing for the same pharma RWE and HEOR budget pools as INEXION.

Direct peers

• ConcertAI: ConcertAI builds oncology-focused real-world evidence and clinical research data products licensed to pharma, overlapping with INEXION's HEOR, RWE, and trial-site-identification revenue lines.
• Verana Health: Verana Health operates specialty real-world data registries (notably in ophthalmology and neurology) by partnering with medical societies to aggregate de-identified clinical data under a unified schema—the same partnership-led registry model INEXION is replicating for longevity medicine.
• Flatiron Health: Flatiron built an oncology-focused longitudinal EMR data registry licensed to pharma for HEOR and RWE, ultimately acquired by Roche for $1.9B. INEXION explicitly cites the Flatiron outcome as its engineering blueprint in longevity rather than oncology.
• COTA Healthcare: COTA curates oncology real-world evidence datasets and analytics for pharma and providers, closely paralleling INEXION's registry-licensing model in a different therapeutic vertical.

Broad incumbents

• IQVIA: IQVIA is the dominant healthcare data and analytics incumbent ($3.5B+ analytics revenue) that INEXION positions against for pharma HEOR and RWE spend, while highlighting IQVIA's architectural blindness to cash-pay longevity cohorts.
• Tempus: Tempus is a named AI/ML training data buyer candidate for INEXION and operates multimodal real-world clinical and molecular data at scale across oncology and beyond. Comparable as a buyer/peer in the AI/ML training corpus category.
• Komodo Health: Komodo operates a claims-based healthcare data platform valued at $3.3B that INEXION identifies as architecturally blind to cash-pay longevity patients. It represents the incumbent RWD alternative for pharma HEOR and RWE spend.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/inexion

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INEXION